Nineteen (63%) individuals experienced treatment-related adverse events (TRAEs), mostly rash (17%), maculopapular rash and fever (13% each), and improved lipase (10%)
Nineteen (63%) individuals experienced treatment-related adverse events (TRAEs), mostly rash (17%), maculopapular rash and fever (13% each), and improved lipase (10%). treatment for 59.7 weeks. Nineteen (63%) individuals experienced treatment-related adverse events (TRAEs), most commonly rash (17%), maculopapular rash and fever (13% each), and improved lipase (10%). Eleven (37%) individuals experienced grade 3 TRAEs; three […]